NovaBay Pharmaceuticals Releases CEO Webcast On Business And Clinical Developments From Its Four Business Units

Audio and Slide Presentation From the Recent Roth Capital Partners 23rd Annual Growth Stock Conference Now Available On-Line

EMERYVILLE, Calif., March 28, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide ^® compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today has provided an on-demand webcast presentation from its CEO, Dr. Ron Najafi. The audio and slide presentation, recently presented at the Roth Capital Partners 23rd Annual Growth Stock Conference, is available at: http://www.wsw.com/webcast/roth24/nby/ . The presentation will be available for 90 days.  

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds.  These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.   NovaBay is focusing its technology on four distinct therapeutic areas:  dermatology, ophthalmology, urology and hospital infections.  In dermatology, the focus is on developing NVC-422 gel for impetigo and acne.  NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world.  In ophthalmology, the goal is to develop an eye drop for conjunctivitis with Alcon, the world's foremost ophthalmology company.  In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections with an irrigation solution containing NVC-422.  In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary antimicrobial solution, NeutroPhase ^TM, which has received two 510K clearances from the Food and Drug Administration. For additional information, visit www.novabaypharma.com .

CONTACT: Investors:
         NovaBay Pharmaceuticals, Inc.
         Thomas J. Paulson, Chief Financial Officer
         510-899-8809
         [e-mail]
         
         Investors and Media:
         The Investor Relations Group
         Investor Relations:
         Adam Holdsworth
         212-825-3210
         [e-mail]
         
         Public Relations:
         Laura Colontrelle
         212-825-3210
         [e-mail]